GS1 Ireland Healthcare User Group (HUG) Information Day

Size: px
Start display at page:

Download "GS1 Ireland Healthcare User Group (HUG) Information Day"

Transcription

1 GS1 Ireland Healthcare User Group (HUG) Information Day Overview on EU FMD regulation and unique identification requirements Geraldine Lissalde-Bonnet, GS1 Global Office 28 th March 2017

2 Overview on EU FMD and unique identification requirements GS1 Ireland HUG Information Day Géraldine Lissalde-Bonnet, GS1 Global Office 28 March 2017, Dublin - Ireland

3 Counterfeit drugs: a global challenge for healthcare Worldwide sales of counterfeit drugs is in excess of $75 billion annually. World Health Organisation: feit/overview/en/ Counterfeits make up more than 10% of the global medicines market. Approximately 1% of counterfeit drugs have penetrated the supply chain in developed countries. European Commission: f2008/wilfried_roge_en.pdf More than 50% of medication and pharmaceuticals purchased online are falsified. World Health Organisation: rvices/counterfeit/overview/en/ 3

4 Around the world 4

5 Traceability/Visibility Very high on the mind of regulatory bodies to address public health issues Different ways and models to implement 5

6 Different approaches Traceability

7 In the EU 7

8 Why the EU FMD? EU Falsified Medicine Directive 2011/62/EU (FMD) EU Commission Delegated Regulation 2016/161 Prevent the entry into the legal supply of falsified medicinal products by requiring the placing of safety features consisting of a unique identifier and an antitampering device on the packaging of certain medicinal products for human use for the purposes of allowing their identification and authentication. 8

9 EU FMD at a glance 1. Safety Features A unique identifier (UI), a unique sequence carried by a 2D barcode allowing the identification and authentication of the individual pack on which it is printed 2 ; An anti-tampering device (ATD) allowing the verification of whether the packaging of the medicinal product has been tampered or not (not relevant for GS1 but regulated under CEN). Verification - Repository system End-to-end verification system of authenticity and integrity of the safety features placed on the packaging of a medicinal product at the time the medicinal product is supplied to the public. Risk-based verifications by wholesale distributors 2. Active substance quality 3. Online pharmacies 9

10 Scope of the EU FMD Medicinal products for human use subject to prescription, unless included in Annex I not subject to prescription which are included in Annex II to which Member States have extended the scope of application of the UI or the ATD Products already on the market may be distributed and supplied to the public in that Member State until their expiry date New or ongoing marketing authorisation products have to be compliant 10

11 Timeline for implementation Applies as of 9 February 2019 Belgium, Greece and Italy have the option of deferring the application of the rules by an additional period of up to 6 years (i.e. 2025) Belgium and Greece announced that they are planning to align with the 2019 timeline 11

12 The EU Unique Identifier 12 Source: EU Commission Stakeholder Meeting, Copyright February GS AISBL, All Rights Reserved.

13 GS1 linear and 2D barcode Item identifier Expiry date (21)123 Batch number Serial number 13

14 GS1 Application Identifiers 01 GTIN (Global Trade Item Number) 14 digit numeric 10 Batch / Lot up to 20 characters - alphanumeric 17 Expiry Date format is YYMMDD so for today Serial Number up to 20 characters - alphanumeric Sequence: GTIN first - then recommend to have fixed length - followed by variable length 14

15 Keep yourself informed Bi-weekly conference calls of specific Public Policy group Contribute and watch the EU FMD Coding Tracker Important information to make changes now Multi-country packs? 15

16 Verification - Repository system: European Stakeholder Model (ESM) A pan-european end-to-end system enabling medicines to be verified at point of dispensing. Source ESM presentations 41

17 Need to be active at the national level The time to act is now 17

18 31 st Global GS1 Healthcare Conference 4 to 6 April 2017, Berlin, Germany Traceability, Unique Device Identification (UDI) and global regulatory developments Use cases and implementations from manufacturers, wholesalers and hospitals what are the experiences, the benefits Patient safety and quality of care how to improve those ThinkTank for regulatory bodies Followed by side visits Participation free for regulatory bodies and hospitals GS1 2017

19 Questions? 19

20 Contact Details Geraldine Lissalde Bonnet Director Public Policy Healthcare GS1 Global Office, Brussels E geraldine.lissalde.bonnet@gs1.org W GS1 2017

Global Track & Trace requirements for better and safer Healthcare

Global Track & Trace requirements for better and safer Healthcare Global Track & Trace requirements for better and safer Healthcare Ulrike Kreysa, VP Healthcare, GS1 Global Office Riyadh, 6 th December 2016 Counterfeiting - The Impact According to Interpol more than

More information

The new European Regulations the Importance of GS1 standards in the Healthcare sector

The new European Regulations the Importance of GS1 standards in the Healthcare sector The new European Regulations the Importance of GS1 standards in the Healthcare sector Safer, more efficient care starts with a simple scan Ulrike Kreysa, Senior Vice-President Healthcare, GS1 Global Office

More information

Background to the Falsified Medicines Directive and the Delegated Regulation. Susan Grieve, Principal Pharmacist, Department of Health 12 April 2016

Background to the Falsified Medicines Directive and the Delegated Regulation. Susan Grieve, Principal Pharmacist, Department of Health 12 April 2016 Background to the Falsified Medicines Directive and the Delegated Regulation Susan Grieve, Principal Pharmacist, Department of Health 12 April 2016 Background to the Falsified Medicines Directive and the

More information

Frequently Asked Questions Secondary care services and the Falsified Medicines Directive (FMD)

Frequently Asked Questions Secondary care services and the Falsified Medicines Directive (FMD) Medicines are the most common intervention made across the NHS. It is essential that patient can have confidence in the medicines they are supplied and that systems are in place to prevent counterfeit

More information

EU IDMP Taskforce Falsified Medicines Directive and European Medicines Verification System Update

EU IDMP Taskforce Falsified Medicines Directive and European Medicines Verification System Update EU IDMP Taskforce Falsified Medicines Directive and European Medicines Verification System Update 19 th February 2016 EMA London Falsified Medicines February 9 th 2016 Delegated Regulation (EU) 2016/161

More information

Supply chain integrity Fighting counterfeiting in healthcare

Supply chain integrity Fighting counterfeiting in healthcare Supply chain integrity Fighting counterfeiting in healthcare The increasing, global threat of counterfeiting in healthcare What is the problem? Counterfeit drugs may harm the patient. Often impossible

More information

Serialisation. GS1 Standards in Healthcare. Standards Certification Education & Training Publishing Conferences & Exhibits

Serialisation. GS1 Standards in Healthcare. Standards Certification Education & Training Publishing Conferences & Exhibits Serialisation GS1 Standards in Healthcare Standards Certification Education & Training Publishing Conferences & Exhibits Siobhain Duggan Director of Innovation and Healthcare at GS1 Ireland Siobhain is

More information

Digital Medicines. FMD in England - Challenges and opportunities in pharmacy

Digital Medicines. FMD in England - Challenges and opportunities in pharmacy Digital Medicines FMD in England - Challenges and opportunities in pharmacy Andrew Davies for Keith Farrar, Senior Responsible Owner Digital Medicines 22 nd November 2017 Falsified medicines and the Falsified

More information

Recommendations on a harmonised implementation of the EU Falsified Medicines Directive using GS1 standards

Recommendations on a harmonised implementation of the EU Falsified Medicines Directive using GS1 standards Executive Summary The EU Falsified Medicines Directive 2011/62/EU (FMD) and the supplementing Commission Delegated Regulation 2016/161 require the interoperability of product verification repositories

More information

The European Stakeholder Model A Medicines Verification System for Europe (ESM)

The European Stakeholder Model A Medicines Verification System for Europe (ESM) The A Medicines Verification System for Europe (ESM) Fighting g counterfeit medicines to ensure patient safety in Europe Martin Friedrich, i Andreas Walter ESM Stakeholders 2013-07-03 European Medicines

More information

Global Serialisation Developments and the Need for Convergence. Ulrike Kreysa, Vice-President, GS1 Global Office 3 rd June 2015

Global Serialisation Developments and the Need for Convergence. Ulrike Kreysa, Vice-President, GS1 Global Office 3 rd June 2015 Global Developments and the Need for Convergence Ulrike Kreysa, Vice-President, GS1 Global Office 3 rd June 2015 Developments across the world Regulatory bodies need to address Public Health issues one

More information

Experience with Serialization Implementation as one powerful measure to protect our patients. Françoise Hirth

Experience with Serialization Implementation as one powerful measure to protect our patients. Françoise Hirth Experience with Serialization Implementation as one powerful measure to protect our patients Françoise Hirth Objectives 1 2 3 Supply Chain integrity & product security A worldwide concern Pharma Industry

More information

Safety Features Required by the Falsified Medicines Directive 2011/62/EU

Safety Features Required by the Falsified Medicines Directive 2011/62/EU TOPRA Annual Human Medicines Symposium 2017 Safety Features Required by the Falsified Medicines Directive 2011/62/EU Syed Qadri, Global Regulatory Affairs Strategy EU/ROW Jazz Pharmaceuticals Syed.Qadri@jazzpharma.com

More information

Implementation of the safety features in medicinal products for human use

Implementation of the safety features in medicinal products for human use Circular published on the INFARMED I.P website in 4 th Sept.2017 Translation of the responsibility of APIFARMA (not official) Information Circular N. º 108/CD/100.20.200 Date: 01/09/1017 Subject: For:

More information

Inside EU FMD and the Delegated Acts A Compliance Primer

Inside EU FMD and the Delegated Acts A Compliance Primer Inside EU FMD and the Delegated Acts A Compliance Primer TABLE OF CONTENTS 01 02 03 04 05 06 EU FMD And Delegated Acts Requirements How Is EU FMD Governed? What Are The Roles For Different Supply Chain

More information

Verification of Pharmaceutical Products at the Point of Dispense. Status of the EFPIA Project

Verification of Pharmaceutical Products at the Point of Dispense. Status of the EFPIA Project Verification of Pharmaceutical Products at the Point of Dispense Speaker : Grant Courtney Status of the EFPIA Project Event: GS1 Global Forum - São Paulo 1 Who is EFPIA? The European Federation of Pharmaceutical

More information

The Blueprint approach

The Blueprint approach the way to comply with FMD and its Delegated Regulation: The Blueprint approach Johan Verhaeghe (FMD Project Manager) Frankfurt, 16 February 2016 EGA Vision 2020 To provide sustainable access to high quality

More information

What To Do or Not To Do? Utility of Medication Traceability to the Patient

What To Do or Not To Do? Utility of Medication Traceability to the Patient What To Do or Not To Do? Utility of Medication Traceability to the Patient Melsen Kwong, Pharm.D. Associate Director Department of Pharmacy Services Cedars-Sinai Medical Center, Los Angeles, CA, USA Objectives

More information

MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents

MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents MHRA GDP Symposium Novotel London West, London 8 & 10 December 2015 Enforcement activities - Impact of the falsified medicines directive Presented by: Peter Blundell, GDP Inspector Impact of the falsified

More information

Implementation of the safety features in medicinal products for human use

Implementation of the safety features in medicinal products for human use Translation of the responsibility of APIFARMA (not official) Information Circular N.º XXX/CD/cód. class. Date: DD/MM/YYYY Subject: For: Implementation of the safety features in medicinal products for human

More information

Top 15 Questions and Answers. EU FMD Safety Features and Verification

Top 15 Questions and Answers. EU FMD Safety Features and Verification Top 15 Questions and Answers EU FMD Safety Features and Verification Now set for early 2019, the Delegated Act on safety features for the European Union (EU) Falsified Medicines Directive (FMD) has pharmaceutical

More information

EU Falsified Medicines Directive. Gareth Jones

EU Falsified Medicines Directive. Gareth Jones EU Falsified Medicines Directive Gareth Jones Why is it important to NPA Members? Will require new processes within community pharmacy from Feb 2019 (barcode scan and tamper check) Requires new IT systems

More information

Falsified Medicines Directive (FMD) Leyla Hannbeck MRPharmS, MBA, MSc, MA NPA Chief Pharmacist and Director of Pharmacy

Falsified Medicines Directive (FMD) Leyla Hannbeck MRPharmS, MBA, MSc, MA NPA Chief Pharmacist and Director of Pharmacy Falsified Medicines Directive (FMD) Leyla Hannbeck MRPharmS, MBA, MSc, MA NPA Chief Pharmacist and Director of Pharmacy Falsified medicines: the facts Falsified medicines may: Be fraudulently mislabelled

More information

Official Journal of the European Union. (Non-legislative acts) REGULATIONS

Official Journal of the European Union. (Non-legislative acts) REGULATIONS 9.2.2016 L 32/1 II (Non-legislative acts) REGULATIONS COMMISSION DELEGATED REGULATION (EU) 2016/161 of 2 October 2015 supplementing Directive 2001/83/EC of the European Parliament and of the Council by

More information

Verification of Pharmaceutical Products at the Point of Dispense. An EFPIA update

Verification of Pharmaceutical Products at the Point of Dispense. An EFPIA update Verification of Pharmaceutical Products at the Point of Dispense Speaker : Grant Courtney Event: GS1 Global Conference Location: Washington An EFPIA update 1 Who is EFPIA? The European Federation of Pharmaceutical

More information

The Danish Generic Medicines Industry Association (IGL)

The Danish Generic Medicines Industry Association (IGL) The Danish Generic Medicines Industry Association (IGL) comments on the concept paper on the delegated act for a unique identifier for medicinal products for human use, and its verification. The Danish

More information

Drug distribution in hospitals and barcoding. The needs of traceability of medicines in hospitals

Drug distribution in hospitals and barcoding. The needs of traceability of medicines in hospitals Drug distribution in hospitals and barcoding The needs of traceability of medicines in hospitals Dr. Roberto Frontini, President EAHP president@eahp.eu Conflict of interest Nothing to disclose Dr. Roberto

More information

Agenda. The Past: 1990 s. Healthcare. Supply Efficiencies Pallet Through Retail Packages The Present:

Agenda. The Past: 1990 s. Healthcare. Supply Efficiencies Pallet Through Retail Packages The Present: Agenda The Past: 1990 s Supply Efficiencies Pallet Through Retail Packages The Present: 2000-2005 Prevention of Dispensing Errors Unit Dose and Unit of Use Packages The Future: 2005 Forward Counterfeit

More information

Medicines Barcoding and Serialization Guideline. National Health Regulatory Authority (NHRA) Kingdom of Bahrain

Medicines Barcoding and Serialization Guideline. National Health Regulatory Authority (NHRA) Kingdom of Bahrain edicines Barcoding and Serialization Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain August 2018 Version 1.0 Chief of Pharmaceutical Product Regulation: Dr / Roaya Al Abbasi Date:

More information

European Union (EU) Falsified Medicines Directive

European Union (EU) Falsified Medicines Directive European Union (EU) Falsified Medicines Directive Mr. Mike Rose, Vice President, Supply Chain Visibility Johnson & Johnson 18 October 2017 GS1 2017 The Promise of Serialization EU Falsified Medicines Directive

More information

Jerome Lepeintre. Delegation of the European Union to China and Mongolia

Jerome Lepeintre. Delegation of the European Union to China and Mongolia Jerome Lepeintre Delegation of the European Union to China and Mongolia EU Falsified Medicine Directive Jerome Lepeintre, Minister Counsellor for Health and, Delegation of the European Union to China and

More information

Implementation Reality - Traceability

Implementation Reality - Traceability Implementation Reality - Traceability GS1 Healthcare Global Conference San Francisco, California, USA Wednesday 2 nd October 2013 Agenda Introduction Case Studies Janice Kite, GS1 Global Office Manufacturer

More information

Chapter Tightening rules on inspections GS1 s users comments: These propositions are the logical consequence of the previous paragraph.

Chapter Tightening rules on inspections GS1 s users comments: These propositions are the logical consequence of the previous paragraph. PUBLIC CONSULTATION IN PREPARATION OF A LEGAL PROPOSAL TO COMBAT COUNTERFEIT MEDICINES FOR HUMAN USE KEY IDEAS FOR BETTER PROTECTION OF PATIENTS AGAINST THE RISK OF COUNTERFEIT MEDICINES Introduction The

More information

The Global Language of Business. Guide to Encode the Unique Identifier on Medicinal Products

The Global Language of Business. Guide to Encode the Unique Identifier on Medicinal Products The Global Language of Business Guide to Encode the Unique Identifier on Medicinal Products Introduction The Directive 2011/62/EU Falsified Medicines Directive aims to establish the safety features necessary

More information

Safety features for medicinal products for human use. Questions & Answers. 1. Document history

Safety features for medicinal products for human use. Questions & Answers. 1. Document history Safety features for medicinal products for human use Questions & Answers This document sets out frequently-asked 'questions and answers' regarding the implementation of the rules on the safety features

More information

The Falsified Medicines Directive. What pharmacy teams need to do

The Falsified Medicines Directive. What pharmacy teams need to do The Falsified Medicines Directive What pharmacy teams need to do Overview Explain the FMD requirements How the authenticity of products will be checked The implications of Brexit The responsibilities of

More information

Healthcare Sector. - Upcoming legislations - GS1 standards. Ann Luyckx Healthcare Manager. Phi Data Event 2018

Healthcare Sector. - Upcoming legislations - GS1 standards. Ann Luyckx Healthcare Manager. Phi Data Event 2018 Healthcare Sector - Upcoming legislations - GS1 standards Ann Luyckx Healthcare Manager Phi Data Event 2018 Anti-trust GS1 Belgium & Luxembourg will not enter into any discussion, activity or conduct that

More information

Welcome to our 29 th Global GS1 Healthcare Conference. Follow us on Twitter and tweet about the #GS1HCuae

Welcome to our 29 th Global GS1 Healthcare Conference. Follow us on Twitter and tweet about the #GS1HCuae Welcome to our 29 th Global GS1 Healthcare Conference Follow us on Twitter and tweet about the conference! @GS1Healthcare #GS1HCuae Welcome to the conference 29 th Global GS1 Healthcare Conference Dubai,

More information

Marking Pharmaceuticals & Medical Devices for the 2012 GTIN Sunrise EXPECTATIONS FOR 2012 AND BEYOND

Marking Pharmaceuticals & Medical Devices for the 2012 GTIN Sunrise EXPECTATIONS FOR 2012 AND BEYOND Marking Pharmaceuticals & Medical Devices for the 2012 GTIN Sunrise EXPECTATIONS FOR 2012 AND BEYOND Contents EXECUTIVE OVERVIEW... 4 DOCUMENT INFORMATION... 5 PURPOSE... 5 AUDIENCE... 5 SCOPE... 5 2012

More information

MAHs and CMOs considerations and objectives to meet upcoming regulations in 2019

MAHs and CMOs considerations and objectives to meet upcoming regulations in 2019 ARVATO SYSTEMS MAHs and CMOs considerations and objectives to meet upcoming regulations in 2019 Pascal Leppich, Arvato Systems Joseph Tshimbalanga, Systec & Services Abcoude, 22 June 2017 The WINDOW is

More information

Health systems and products Medical products quality, safety and innovation VERSION 8

Health systems and products Medical products quality, safety and innovation VERSION 8 EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems and products Medical products quality, safety and innovation SAFETY FEATURES FOR MEDICINAL PRODUCTS FOR HUMAN USE QUESTIONS

More information

Federal agency for medicines and health products. Seminar LM4: Falsified Medicines Directive - Did they forget the hospital pharmacy?

Federal agency for medicines and health products. Seminar LM4: Falsified Medicines Directive - Did they forget the hospital pharmacy? Federal agency for medicines and health products Seminar LM4: Falsified Medicines Directive - Did they forget the hospital pharmacy? Philippe De Buck 23-24 march 2017 22 nd Congress of the European Association

More information

Serialization Primer

Serialization Primer Serialization Primer Introduction Global pharmaceutical distribution networks and supply chains have become more complex and interconnected, quickening the pace of regulations that mandate pharmaceutical

More information

A FREQUENTZ WHITE PAPER: Meeting Traceability Regulations In The World s Two Largest Pharmaceutical Markets Frequentz. All rights reserved.

A FREQUENTZ WHITE PAPER: Meeting Traceability Regulations In The World s Two Largest Pharmaceutical Markets Frequentz. All rights reserved. Meeting Traceability Regulations In The World s Two Largest Pharmaceutical Markets Introduction John Schultz john.schultz@frequentz.com Regulations mandating the serialization and tracing of pharmaceuticals

More information

Falsified Medicines Directive: Irish Medicines Verification Organisation (IMVO) update for HPRA GMP Conference LEONIE CLARKE - 7 TH FEBRUARY 2017

Falsified Medicines Directive: Irish Medicines Verification Organisation (IMVO) update for HPRA GMP Conference LEONIE CLARKE - 7 TH FEBRUARY 2017 Falsified Medicines Directive: Irish Medicines Verification Organisation (IMVO) update for HPRA GMP Conference LEONIE CLARKE - 7 TH FEBRUARY 2017 Safety Features Falsified Medicines Directive(2011/62/EU)

More information

GS1 Healthcare Newsletter

GS1 Healthcare Newsletter No. 25 Q4 2012 table of contents Special feature: GS1 Healthcare Conference Gathers in Lisbon 1 GS1 Healthcare takes the stage in Lisbon 1 McKinsey & Company reports on the benefits a single global standard

More information

Future in Pharmaceuticals. The countdown to Serialisation and the benefits of implementing GS1 Standards

Future in Pharmaceuticals. The countdown to Serialisation and the benefits of implementing GS1 Standards Future in Pharmaceuticals The countdown to Serialisation and the benefits of implementing GS1 Standards GS1 Ireland Healthcare 26 th February 2014 New McKinsey & Company report on benefits of a single

More information

GS1 Healthcare - Discussion paper on multi-market packs for pharmaceutical products

GS1 Healthcare - Discussion paper on multi-market packs for pharmaceutical products Purpose This GS1 Healthcare paper has been written to help demonstrate ways in which GS1 bar codes can be used to minimise the need for multiple bar codes to appear on product packaging while still enabling

More information

Saudi Drug Code (SDC), and Drug Barcoding Specifications

Saudi Drug Code (SDC), and Drug Barcoding Specifications Drug Sector Licensing Executive Directorate Guidance for Industry Saudi Drug Code (SDC), and Drug Barcoding Specifications This document outlines the SDC and the new drug barcode requirements for pharmaceuticals.

More information

NEW EU Regulations and the EU UDI system

NEW EU Regulations and the EU UDI system NEW EU Regulations and the EU UDI system 24 October 2017, Brussels Géraldine Lissalde-Bonnet Director Public Policy, GS1 Global Office Disclaimer Neither GS1 nor its member organizations nor their staffs

More information

Update Version 1.0 Based on the information available at that date of NCA.

Update Version 1.0 Based on the information available at that date of NCA. Update 05.2017 Version 1.0 Based on the information available at that date of NCA. 1 Check if your company is affected: check the scope of the Falsified Medicines Directive (FMD) = Download general presentation

More information

The value partnership between NHS, industry and other providers

The value partnership between NHS, industry and other providers The value partnership between NHS, industry and other providers Dr Richard Greville, Director Wales and Director Distribution & Supply, ABPI 12 April 2016 The Value Partnership between NHS, Industry and

More information

Unique Device Identifier (UDI) Labeling

Unique Device Identifier (UDI) Labeling INFORMATION SHEET Unique Device Identifier (UDI) Labeling On September 24, 2013, the United States Food and Drug Administration (FDA) released a final rule requiring that most medical devices distributed

More information

Regulatory Update: The US Drug Supply Chain Security Act (DSCSA) December 2017

Regulatory Update: The US Drug Supply Chain Security Act (DSCSA) December 2017 Regulatory Update: The US Drug Supply Chain Security Act (DSCSA) December 2017 Regulatory Agency Regulation Name or System Name Compliance Dates U.S. Department of Health and Human Services (HHS), Food

More information

FMD error and alert messages guidance notes To accompany FMD scanning and alert messages chart (v7) December 2018 UPDATED GUIDANCE

FMD error and alert messages guidance notes To accompany FMD scanning and alert messages chart (v7) December 2018 UPDATED GUIDANCE Falsified Medicines Directive FMD error and alert messages guidance notes To accompany FMD scanning and alert messages chart (v7) December 2018 UPDATED GUIDANCE These guidance notes accompany the FMD error

More information

Health systems and products Medical products quality, safety and innovation

Health systems and products Medical products quality, safety and innovation EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems and products Medical products quality, safety and innovation SAFETY FEATURES FOR MEDICINAL PRODUCTS FOR HUMAN USE QUESTIONS

More information

Government and regulatory body ThinkTank

Government and regulatory body ThinkTank Government and regulatory body ThinkTank Day 1: Learning from donor agencies on procurement and the support of local regulation GS1 Healthcare African Conference 8 May 2018, Addis Ababa, Ethiopia GS1 2018

More information

GS1 standards for unique identification of medicinal products

GS1 standards for unique identification of medicinal products GS1 standards for unique identification of medicinal products Lisbon, Portugal 3 July 2013 Silverio Paixão, Chief Innovation & Standards Officier, GS1 Portugal Who is GS1? GS1 a neutral, not-for-profit,

More information

Regulating risks of falsified medicinal products in the legal distribution chain Safety features - Legal and Regulatory issues

Regulating risks of falsified medicinal products in the legal distribution chain Safety features - Legal and Regulatory issues Regulating risks of falsified medicinal products in the legal distribution chain Safety features - Legal and Regulatory issues Annika Wennberg, Medical Products Agency New definition Falsified human medicinal

More information

Health Business Services One Voice for Health Procurement GS1 Healthcare User Group (HUG) Briefing

Health Business Services One Voice for Health Procurement GS1 Healthcare User Group (HUG) Briefing Health Business Services One Voice for Health Procurement GS1 Healthcare User Group (HUG) Briefing Agenda Introduction Overview Health Business Services Next Steps HBS Strategy for adoption of GS1 Standards

More information

A closer look at the EU- FMD Safety Features Delegated Act: 10 things pharma manufacturers need to consider

A closer look at the EU- FMD Safety Features Delegated Act: 10 things pharma manufacturers need to consider August 2015 A closer look at the EU- FMD Safety Features Delegated Act: 10 things pharma manufacturers need to consider It is the general consensus amongst close observers that the draft of the EU- Falsified

More information

Evaluation of Counterfeit Cases Impact of FMD & GDPs. Lorraine Nolan Healthcare Products Distribution Manager

Evaluation of Counterfeit Cases Impact of FMD & GDPs. Lorraine Nolan Healthcare Products Distribution Manager Evaluation of Counterfeit Cases Impact of FMD & GDPs Wholesale Distribution Information Day, 28th September 2012 Lorraine Nolan Healthcare Products Distribution Manager Slide 1 Contents 1. Review of UK

More information

SERIALIZATION. Counterfeit Medicines: A Worldwide Problem

SERIALIZATION. Counterfeit Medicines: A Worldwide Problem SERIALIZATION Counterfeit Medicines: A Worldwide Problem SERIALIZATION COUNTERFEIT MEDICINES: A WORLDWIDE PROBLEM By Olivier Feraille, Cognex Corporation 10% OF MEDICINES AROUND THE WORLD COULD BE COUNTERFEIT

More information

Discussion paper on recent developments of the Russian system of goods labelling with identification means

Discussion paper on recent developments of the Russian system of goods labelling with identification means Purpose The purpose of this paper is to facilitate the discussions about the establishment of a globally harmonised system for traceability of pharmaceuticals withinrussia, but also between Russia and

More information

EXISTING TECHNOLOGIES AND TRACK AND TRACE MODELS IN USE AND TO BE DEVELOPED BY MEMBER STATES. TABLE: EXPERIENCES IN COUNTRIES (updated November 2017)

EXISTING TECHNOLOGIES AND TRACK AND TRACE MODELS IN USE AND TO BE DEVELOPED BY MEMBER STATES. TABLE: EXPERIENCES IN COUNTRIES (updated November 2017) EXISTING TECHNOLOGIES AND TRACK AND TRACE MODELS IN USE AND TO BE DEVELOPED BY MEMBER STATES TABLE: EXPERIENCES IN COUNTRIES (updated November 2017) In November 2017, the Table: Experiences in Countries

More information

Verification processes in the supply chain. Workshop for MAHs, Helsinki, 18 Sep 2018 Teijo Yrjönen, FiMVO

Verification processes in the supply chain. Workshop for MAHs, Helsinki, 18 Sep 2018 Teijo Yrjönen, FiMVO Verification processes in the supply chain Workshop for MAHs, Helsinki, 18 Sep 2018 Teijo Yrjönen, FiMVO Legislative background Directive 2011/62/EU (Falsified Medicines Directive) Commission Delegated

More information

UDI (Unique Device Identification) and patient safety latest regulatory developments

UDI (Unique Device Identification) and patient safety latest regulatory developments UDI (Unique Device Identification) and patient safety latest regulatory developments Ulrike Kreysa, VP Healthcare, GS1 Global Office Medical Devices Innovation Program Munich, 14 October 2016 Agenda UDI

More information

Manufacturers serialisation challenges with FMD & DR implementation

Manufacturers serialisation challenges with FMD & DR implementation Manufacturers serialisation challenges with FMD & DR implementation Mike Rose Vice President, Supply Chain Visibility, Johnson & Johnson Supply Chain Chairman of EFPIA s Supply Chain WG & FMD Implementation

More information

Meeting UDI-requirements - Lessons Learnt and Customer Perspective LSA2018

Meeting UDI-requirements - Lessons Learnt and Customer Perspective LSA2018 Meeting UDI-requirements - Lessons Learnt and Customer Perspective LSA2018 Sylvia Reingardt, Senior Sector Manager Healthcare, GS1 Germany July 4, 2018 MediaDocks Lübeck Disclaimer Neither GS1 nor its

More information

Position Paper (I) Healthcare Provider Advisory Council Interoperability of Information Technology Systems

Position Paper (I) Healthcare Provider Advisory Council Interoperability of Information Technology Systems I. i Introduction Position Paper (I) Towards the end of 2011, GS1 Healthcare established the Healthcare Provider Advisory Council (HPAC) to be the forum for sharing and discussing the practical realities

More information

Regulatory Roadmap: Traceability of Medicinal Products

Regulatory Roadmap: Traceability of Medicinal Products Regulatory Roadmap: Traceability of Medicinal Products October 2018 Disclaimer: Neither GS1 nor its member organisations nor their staffs have real or apparent authority to speak for the regulatory authorities.

More information

Membership Registration Form. Company Details

Membership Registration Form. Company Details Membership Registration Form This form allows you to become a voting or non-voting member of GS1 Healthcare, the global healthcare user group. GS1 Healthcare welcomes the following stakeholders as voting

More information

IMPLEMENTAÇÃO DA DIRETIVA DOS MEDICAMENTOS FALSIFICADOS E ATOS DELEGADOS. Pedro Ferreira ANF

IMPLEMENTAÇÃO DA DIRETIVA DOS MEDICAMENTOS FALSIFICADOS E ATOS DELEGADOS. Pedro Ferreira ANF IMPLEMENTAÇÃO DA DIRETIVA DOS MEDICAMENTOS FALSIFICADOS E ATOS DELEGADOS Pedro Ferreira ANF What are falsified medicines? Growing threat to public health and safety in Europe Counterfeit medicines seized

More information

The world of GS1 standards in healthcare. Chris Adcock GS1 Global Office

The world of GS1 standards in healthcare. Chris Adcock GS1 Global Office The world of GS1 standards in healthcare Chris Adcock GS1 Global Office Topics Background Where we are going Where we are today What this means to you Questions Background Topics Where we are going Where

More information

Mass Serialization and Traceability Implementation in the Pharma Industry. Mathieu Aman, Global Program Lead F. Hoffmann-La Roche Ltd, Switzerland

Mass Serialization and Traceability Implementation in the Pharma Industry. Mathieu Aman, Global Program Lead F. Hoffmann-La Roche Ltd, Switzerland Mass Serialization and Traceability Implementation in the Pharma Industry Mathieu Aman, Global Program Lead F. Hoffmann-La Roche Ltd, Switzerland What drives the industry towards more traceability Strategic

More information

What Is Next After the Results of Implementing GS1 Pilot in the Public Health Supply Chains!

What Is Next After the Results of Implementing GS1 Pilot in the Public Health Supply Chains! What Is Next After the Results of Implementing GS1 Pilot in the Public Health Supply Chains! ongoing progress in Pakistan Dr. Muhammad Tariq, Country Director, Pakistan Field Office USAID Global Health

More information

Falsified Medicines Directive: Overview from the Irish Medicines Verification Organisation (IMVO) LEONIE CLARKE - 28 TH MARCH HUG

Falsified Medicines Directive: Overview from the Irish Medicines Verification Organisation (IMVO) LEONIE CLARKE - 28 TH MARCH HUG Falsified Medicines Directive: Overview from the Irish Medicines Verification Organisation (IMVO) LEONIE CLARKE - 28 TH MARCH 2017 - HUG EU requirements * for repositories of unique identifiers Every MS

More information

Welcome to our 29 th Global GS1 Healthcare Conference. Follow us on Twitter and tweet about the #GS1HCuae

Welcome to our 29 th Global GS1 Healthcare Conference. Follow us on Twitter and tweet about the #GS1HCuae Welcome to our 29 th Global GS1 Healthcare Conference Follow us on Twitter and tweet about the conference! @GS1Healthcare #GS1HCuae GS1 2016 Dr. Ina Trapp Roche Diagnostics Implementation of GS1 barcode

More information

GS1 Guide on Unique Device Identification (UDI) implementation

GS1 Guide on Unique Device Identification (UDI) implementation GS1 Guide on Unique Device Identification (UDI) implementation This document aims at providing clarification to questions raised by the industry as well as implementation guidance on the use of GS1 standards.

More information

Implementation Reality Traceability

Implementation Reality Traceability Implementation Reality Traceability How to enable/implement traceability? 2 nd April 2014, Seoul/Korea Round 1 (13:30 15:00) Moderator Grant Courtney, Business Lead, Fingerprint Serialisation, Global Manufacturing

More information

GS1 Ireland Healthcare User Group (HUG) Information Day

GS1 Ireland Healthcare User Group (HUG) Information Day GS1 Ireland Healthcare User Group (HUG) Information Day FMD Implementation challenges for the manufacturers Joan Cahill, Pfizer 28 th March 2017 FMD Implementation Challenges Industry Perspective Joan

More information

Conferencia. Tendencias Globales en Seguridad del Paciente desde la Cadena de Abastecimiento

Conferencia. Tendencias Globales en Seguridad del Paciente desde la Cadena de Abastecimiento Conferencia Tendencias Globales en Seguridad del Paciente desde la Cadena de Abastecimiento Today s Healthcare landscape Worldwide sales of counterfeit drugs is in excess of $75 billion annually. World

More information

DAVA. Drugs Authentication and Verification Application. A portal for Indian Drugs authentication, track and trace

DAVA. Drugs Authentication and Verification Application. A portal for Indian Drugs authentication, track and trace DAVA Drugs Authentication and Verification Application A portal for Indian Drugs authentication, track and trace Avinash Pedgaonkar 15-12-2015 Objectives To ensure the genuineness and authenticity of the

More information

Scan4Safety. Implications on Hospital Pharmacy and effect on delivery of healthcare November 2017

Scan4Safety. Implications on Hospital Pharmacy and effect on delivery of healthcare November 2017 Scan4Safety Implications on Hospital Pharmacy and effect on delivery of healthcare November 2017 Evolution NHS eprocurement strategy GS1 and PEPPOL Scan4Safety Audience Patients Trusts Suppliers Technology

More information

Timeline for the Drug Supply Chain and Security Act

Timeline for the Drug Supply Chain and Security Act April 2014 Timeline for the Drug Supply Chain and Security Act (Title II, Drug Quality and Security Act, 2013) Overview The Drug Supply Chain and Security Act (Title II, Drug Quality and Security Act,

More information

The way forward for FMD in community pharmacy

The way forward for FMD in community pharmacy The way forward for FMD in community pharmacy Introduction This document represents the consolidated views of the UK FMD Working Group for Community Pharmacy on the implementation of the safety features

More information

The role of the European Commission during the FMD implementation phase Agnès Mathieu DG SANTE European Commission

The role of the European Commission during the FMD implementation phase Agnès Mathieu DG SANTE European Commission The role of the European Commission during the FMD implementation phase Agnès Mathieu DG SANTE European Commission 1st EMVO-MS Workshop 13 December 2016 Delegated Regulation on the Safety Features Adoption

More information

The Past, the Present and the Future that GS1 Healthcare Standards will deliver for the African Continent

The Past, the Present and the Future that GS1 Healthcare Standards will deliver for the African Continent The Past, the Present and the Future that GS1 Healthcare Standards will deliver for the African Continent African GS1 Healthcare Conference, Addis Ababa, Ethiopia Tunde Odunlami, CEO GS1 Nigeria 8 May,

More information

EAHP STATEMENT ON THE NEED FOR BARCODING OF THE SINGLE DOSE ADMINISTERED IN HOSPITALS

EAHP STATEMENT ON THE NEED FOR BARCODING OF THE SINGLE DOSE ADMINISTERED IN HOSPITALS EAHP STATEMENT ON THE NEED FOR BARCODING OF THE SINGLE DOSE ADMINISTERED IN HOSPITALS JUNE 2012 (UPDATED FROM 2007 & 2010 STATEMENTS) What is meant by barcoding of the single dose? By single dose EAHP

More information

Pharmaceutical Serialization in Brasil. 12 Mar 2015

Pharmaceutical Serialization in Brasil. 12 Mar 2015 Pharmaceutical Serialization in Brasil 12 Mar 2015 Agenda Introduction Serialization Supply Chain Overview Global Regulatory Snapshot Discussion and Comparison of RDC No. 54 (Brasil Law) Key Impact Considerations

More information

A global view from the Pharmaceutical Industry Mathieu Aman F. Hoffmann-La Roche Ltd, Basel (Switzerland)

A global view from the Pharmaceutical Industry Mathieu Aman F. Hoffmann-La Roche Ltd, Basel (Switzerland) Impressions Kaiseraugst A global view from the Pharmaceutical Industry Mathieu Aman F. Hoffmann-La Roche Ltd, Basel (Switzerland) SETRM2016 Rastreabilidade de Medicamento Sao Paulo, Jun 2016 Agenda Worldwide,

More information

Belgian Medicines Verification Organisation. End User Implementation

Belgian Medicines Verification Organisation. End User Implementation Belgian Medicines Verification Organisation End User Implementation End User implementation Agenda Project planning and status End user FMD activity Controlled on boarding for early bird end users End

More information

Health systems and products Medical products quality, safety and innovation

Health systems and products Medical products quality, safety and innovation EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems and products Medical products quality, safety and innovation SAFETY FEATURES FOR MEDICINAL PRODUCTS FOR HUMAN USE QUESTIONS

More information

Practical implementation of the Falsified Medicines Directive

Practical implementation of the Falsified Medicines Directive Practical implementation of the Falsified Medicines Directive Belén Escribano Romero Head of Pharmaceutical Inspection and Enforcement Department AEMPS 1 Content Development of the Directive Overview of

More information

Along with this the interesting aspects of varied solutions different countries and continents are exploring.

Along with this the interesting aspects of varied solutions different countries and continents are exploring. The past months, have been fascinating for those of us watching developments in the drive to increase security in the food and pharmaceutical industry. Along with this the interesting aspects of varied

More information

ACCOUNTABILITY AND TRANSPARENCY IN PHARMA SUPPLY CHAIN 6/26/2018. Presentation to UN 2018 Public Service Forum. Richard Bergström External Lead Pharma

ACCOUNTABILITY AND TRANSPARENCY IN PHARMA SUPPLY CHAIN 6/26/2018. Presentation to UN 2018 Public Service Forum. Richard Bergström External Lead Pharma ACCOUNTABILITY AND TRANSPARENCY IN PHARMA SUPPLY CHAIN Presentation to UN 2018 Public Service Forum Richard Bergström External Lead Pharma Enabling trust 1 SICPA: GLOBAL ROLE Protection of 85+% world currency

More information

Implementation of EU Falsified Medicines Directive

Implementation of EU Falsified Medicines Directive Implementation of EU Falsified Medicines Directive Gerald W Heddell Director, Inspection, Enforcement & Standards Division 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views

More information

Barcodes on Unit of Use

Barcodes on Unit of Use Barcodes on Unit of Use 1 What hospitals need Hospitals need medications Ready-to-Administer In Unit-of-Use With Barcode 2 What hospitals need Ready-to-Administer If not, must go through additional pharmacy

More information

Falsified Medicines Directive Info session for MAHs

Falsified Medicines Directive Info session for MAHs Falsified Medicines Directive Info session for MAHs 25/4/2017 14u 17u Auditorium at Wolubilis Agenda Welcome MAH responsibilities in FMD Products to market Q&A Interaction with the Verification system

More information

Project responsibilities

Project responsibilities Project responsibilities Tallinn November 24th, 2017 Our Mission Falsified / counterfeit medicines are a serious risk for the citizens all around the world New legislation published on the 9th February

More information